Non-invasive DNA prenatal detection technology only needs to extract the venous blood of pregnant women, use the new generation DNA sequencing technology to sequence the free DNA fragments in the peripheral plasma of pregnant women, and analyze the biological information of the sequencing results to obtain the genetic information of the fetus, so as to detect whether the fetus has three chromosome diseases.
Internationally, this technology has been developed and put into service in the United States, and the companies providing this technology are Sequenom and Natera. And in some areas (states), the cost of this test can be borne by commercial insurance, so it is very popular with pregnant women, especially elderly pregnant women.
Extended data:
Although the detection accuracy of non-invasive DNA prenatal detection technology is as high as 98%, and it is simple, rapid and non-invasive, it is not suitable for all people.
This technique is used to screen Down syndrome, but it cannot screen all genetic diseases.
In addition, the test is not recommended for pregnant women with a history of fetal delivery with chromosomal abnormalities, pregnant women who have received allogeneic blood transfusion, transplantation, cell therapy or immunotherapy within one year, and high-risk groups with various genetic diseases.
However, at present, the non-invasive DNA screening technology can only accurately screen out the number abnormalities of 3 pairs of chromosomes: 2 1, 18 and 13, while the traditional amniocentesis can comprehensively check 23 pairs of chromosomes and their structural abnormalities of the fetus. High-risk pregnant women who should be diagnosed by amniocentesis must be amniocentesis in a strict sense, which is irreplaceable by non-invasive DNA prenatal screening.
People's Health Network-How accurate is non-invasive prenatal genetic testing?